These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10532192)

  • 1. Present achievements in the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Debled M
    Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192
    [No Abstract]   [Full Text] [Related]  

  • 2. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for advanced renal cell cancer].
    Schmidt S; Kunath F; Kroeger N
    Urologe A; 2015 May; 54(5):716-20. PubMed ID: 25987336
    [No Abstract]   [Full Text] [Related]  

  • 4. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of extensive metastatic renal cancer following immunotherapy.
    Plowman PN; Costello J; O'Donoghue N
    Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of adoptive immunotherapy in solid cancers.
    Kruit WH; Stoter G
    Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
    Taneja SS; Pierce W; Figlin R; Belldegrun A
    Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
    [No Abstract]   [Full Text] [Related]  

  • 12. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?
    Young RC
    N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D
    Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytoreductive nephrectomy in metastatic renal cancer.
    Flanigan RC
    Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 16. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
    Oliver RT
    Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removing the primary tumor after the cancer has spread.
    Tannock IF
    N Engl J Med; 2001 Dec; 345(23):1699-700. PubMed ID: 11759650
    [No Abstract]   [Full Text] [Related]  

  • 19. [The role of immunotherapy in metastatic cancer of the kidney].
    Thiounn N
    J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.